Intensive Care Tactics for Reducing Gastrointestinal Bleeding in the Context of Portal Hypertension

Introduction. Gastrointestinal bleeding is currently one of the most significant pathologies indicating lethality. Factors in the incidence of gastrointestinal bleeding include the spread of gastrointestinal diseases caused by eating disorders, Helicobacter Pylori infection and routine use of anticoagulants. The various causes leading to the development and level of bleeding in the gastrointestinal tract require a differentiated therapeutic approach. In addition to surgical haemostasis, pharmacological support is also required. In the article, we consider medicamentous therapeutic approaches to bleeding due to phlebeurysm, which is one of the most common causes of gastrointestinal bleeding. This problem is very relevant due to the spread of hepatitis and alimentary toxicity having cirrhosis as the outcome.
Materials and methods. The review considers the priority methods for treatment of patients with gastrointestinal bleeding, depending on the etiopathogenetic factors.
Conclusion. Adequate pharmacotherapy of bleeding from varicose veins of the esophagus is more important than surgical interventions, both for prevention and for haemostasis and subsequent control of the development of re-bleeding. Obviously, the use of vasoactive drugs improves the prognosis and effectiveness of endoscopic ligation of esophageal varicose veins, balloon tamponade, portosystemic shunting, and beta-blockers play a significant role in primary and secondary prevention.

1. Jakab S.S., Garcia-Tsao G. Screening and surveillance of varices in patients with cirrhosis. Clin Gastroenterol Hepatol. 2018 Mar 15: S1542–3565(18)30267–2. DOI: 10.1016/j.cgh.2018.03.012

2. Bosch J., Groszmann R.J., Shah V.H. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62(1 Suppl):S121–30. DOI: 10.1016/j.jhep.2015.01.003

3. Garcia-Tsao G., Bosch J. Varices and variceal hemorrhage in cirrhosis: a new view of an old problem. Clin Gastroenterol Hepatol. 2015;13(12):2109–17. DOI: 10.1016/j.cgh.2015.07.012

4. Berzigotti A., Bosch J. Pharmacologic management of portal hypertension. Clin Liver Dis. 2014;18(2):303–17. DOI: 10.1016/j.cld.2013.12.003

5. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762–8. DOI: 10.1016/j.jhep.2010.06.004

6. National Institute for Health and Clinical Excellence. Acute upper gastrointestinal bleeding: management: clinical guideline. Manchester, 2012. 24 p.

7. D’Amico G., Pasta L., Morabito A., D’Amico M., Caltagirone M., Malizia G. et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93. DOI: 10.1111/apt.12721

8. Garcia-Tsao G., Abraldes J.G., Berzigotti A., Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310–35. DOI: 10.1002/hep.28906

9. Sinagra E., Perricone G., D’Amico M., Tinè F., D’Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39(6):557–68. DOI: 10.1111/apt.12634

10. Reiberger T., Ulbrich G., Ferlitsch A., Payer B.A., Schwabl P., Pinter M. et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62(11):1634–41. DOI: 10.1136/gutjnl-2012-304038

11. Stanley A.J., Dickson S., Hayes P.C., Forrest E.H., Mills P.R., Tripathi D. et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol. 2014;61(5):1014–9. DOI: 10.1016/j.jhep.2014.06.015

12. Shah H.A., Azam Z., Rauf J., Abid S., Hamid S., Jafri W. et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol. 2014;60(4):757–64. DOI: 10.1016/j.jhep.2013.11.019

13. Cotoras Viedma P., Candia R. Banding ligation or beta-blockers for primary prevention of variceal bleeding? Medwave. 2016;16(Suppl5):e6564. DOI: 10.5867/medwave.2016.6564

14. Young Dae Kim Management of acute variceal bleeding. Clin Endosc. 2014;47(4):308–14. DOI: 10.5946/ce.2014.47.4.308

15. Villanueva C., Colomo A., Bosch A., Concepcion M., Hernandez-Gea V., Aracil C. et al. Transfusion strategies for acute upper gastrointestinal bleeding. New Engl J Med. 2013;368:11–21. DOI: 10.1056/NEJMoa1211801

16. Bendtsen F., D’Amico G., Rusch E., de Franchis R., Andersen P.K., Lebrec D. et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol. 2014;61:252–9. DOI: 10.1016/j.jhep.2014.03.035

17. Chavez-Tapia N.C., Barrientos-Gutierrez T., Tellez-Avila F., Soares-Weiser K., Mendez-Sanchez N., Gluud C. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding — an updated Cochrane review. Aliment Pharmacol Ther. 2011;34(5):509–18. DOI: 10.1111/j.1365-2036.2011.04746.x

18. Lee Y.Y., Tee H.P., Mahadeva S. Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. World J Gastroenterol. 2014;20(7):1790–6. DOI: 10.3748/wjg.v20.i7.1790

19. Lo G.H., Perng D.S., Chang C.Y., Tai C.M., Wang H.M., Lin H.C. Controlled trial of ligation plus vasoconstrictor versus proton pump inhibi tor in the control of acute esophageal variceal bleeding. J Gastroenterol Hepatol. 2013;28(4):684–9. DOI: 10.1111/jgh.12107

20. Wang C., Han J., Xiao L., Jin C.E., Li D.J., Yang Z. Efficacy of vasopressin/ terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis. Hepatol Int. 2015;9(1):120–9. DOI: 10.1007/s12072-014-9594-9

21. Gluud L.L., Langholz E., Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther. 2010;32(7):859–71. DOI: 10.1111/j.1365-2036.2010.04418.x

22. Lo G.H., Chen W.C., Wang H.M., Yu H.C. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol. 2012;27(11):1681–7. DOI: 10.1111/j.1440-1746.2012.07244.x

23. Seo Y.S., Park S.Y., Kim M.Y., Kim J.H., Park J.Y., Yim H.J. et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60(3):954–63. DOI: 10.1002/hep.27006

24. Wells M., Chande N., Adams P., Beaton M., Levstik M., Boyce E. et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267–78. DOI: 10.1111/j.1365-2036.2012.05088.x

25. Salim A., Malik K., Haq I.U., Butt A.K., Alam A. Comparison of 12- hour with 72-hour terlipressin therapy for bleeding esophageal varices. J Coll Physicians Surg Pak. 2017;27(6):334–7. PMID: 28689520

26. Lin L.L., Du S.M., Fu Y., Gu H.Y., Wang L., Jian Z.Y. et al. Combination therapy versus pharmacotherapy, endoscopic variceal ligation, or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(34):57399–408. DOI: 10.18632/oncotarget.18143

27. Lo G.H. Endoscopic therapy plus beta blocker is still the first choice for prevention of variceal rebleeding? Hepatology. 2016;64(5):1816–7. DOI: 10.1002/hep.28665

28. Chitapanarux T., Ritdamrongthum P., Leerapun A., Pisespongsa P., Thongsawat S. Three-day versus five-day somatostatin infusion combination with endoscopic variceal ligation in the prevention of early rebleeding following acute variceal hemorrhage: A randomized controlled trial. Hepatol Res. 2015;45(13):1276–82. DOI: 10.1111/hepr.12503

29. Chen J., Zeng X.Q., Ma L.L., Li B., Tseng Y.J., Lian J.J. et al. Randomized controlled trial comparing endoscopic ligation with or without sclerotherapy for secondary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol. 2016;28(1):95–100. DOI: 10.1097/MEG.0000000000000499

30. Patel M., Molvar Ch. Evolution of retrograde transvenous obliteration techniques. Semin Intervent Radiol. 2018; 35(3):185–93. DOI: 10.1055/s-0038-1660796

31. Escorsell A., Pavel O., Cardenas A., Morillas R., Llop E., Villanueva C. et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology. 2016;63(6):1957–67. DOI: 10.1002/hep.28360

32. Tantau M., Crisan D., Popa D., Vesa S., Tantau A. Band ligation vs. N-butyl-2-cyanoacrylate injection in acute gastric variceal bleeding: a prospective follow-up study. Ann Hepatol. 2013;13(1):75–83. PMID: 24378269

33. Qi X., Liu L., Bai M., Chen H., Wang J., Yang Z. et al. Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding: a meta-analysis. J Gastroenterol. Hepatol. 2014;29(4):688–96. DOI: 10.1111/jgh.12391

34. Njei B., McCarty T.R., Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. J Gastroenterol Hepatol. 2017;32(4):852–8. DOI: 10.1111/jgh.13593

35. Garcia-Pagan J.C., Di Pascoli M., Caca K., Laleman W., Bureau C., Appenrodt B. et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58(1):45–50. DOI: 10.1016/j.jhep.2012.08.020